Clinical Trial Update: A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of ipilimumab and fotemustine for unresectable locally advanced or metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Fotemustine (fotemustine)
• Yervoy (Ipilimumab) (Ipilimumab)

Snippet

Sponsor: Italian Network for Tumor Biotherapy | Conditions: Metastatic Malignant Melanoma | Phase 2 | Status: COMPLETED